JP2009538386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538386A5 JP2009538386A5 JP2009512295A JP2009512295A JP2009538386A5 JP 2009538386 A5 JP2009538386 A5 JP 2009538386A5 JP 2009512295 A JP2009512295 A JP 2009512295A JP 2009512295 A JP2009512295 A JP 2009512295A JP 2009538386 A5 JP2009538386 A5 JP 2009538386A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lmwh
- composition according
- activity
- surgical intervention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 122
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 113
- 230000000694 effects Effects 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 20
- 238000011477 surgical intervention Methods 0.000 claims description 19
- 230000001858 anti-Xa Effects 0.000 claims description 16
- 229920000669 heparin Polymers 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 239000003495 polar organic solvent Substances 0.000 claims description 10
- 102000007327 Protamines Human genes 0.000 claims description 9
- 108010007568 Protamines Proteins 0.000 claims description 9
- 150000002016 disaccharides Chemical class 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 206010053567 Coagulopathies Diseases 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 230000035602 clotting Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229950008679 protamine sulfate Drugs 0.000 claims description 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 3
- 102000002262 Thromboplastin Human genes 0.000 claims description 3
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108010022901 Heparin Lyase Proteins 0.000 claims description 2
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 claims description 2
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 claims description 2
- 208000007718 Stable Angina Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 2
- 150000002482 oligosaccharides Polymers 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 241000287463 Phalacrocorax Species 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 238000007820 coagulation assay Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- 238000012544 monitoring process Methods 0.000 description 5
- 229940048914 protamine Drugs 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229960000610 enoxaparin Drugs 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 150000008273 hexosamines Chemical class 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical class OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- CENHPXAQKISCGD-UHFFFAOYSA-N trioxathietane 4,4-dioxide Chemical compound O=S1(=O)OOO1 CENHPXAQKISCGD-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80913606P | 2006-05-25 | 2006-05-25 | |
| US84957806P | 2006-10-04 | 2006-10-04 | |
| US84962806P | 2006-10-05 | 2006-10-05 | |
| PCT/US2007/069626 WO2007140231A2 (en) | 2006-05-25 | 2007-05-24 | Low molecular weight heparin composition and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009538386A JP2009538386A (ja) | 2009-11-05 |
| JP2009538386A5 true JP2009538386A5 (enExample) | 2010-06-17 |
Family
ID=38722686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512295A Pending JP2009538386A (ja) | 2006-05-25 | 2007-05-24 | 低分子量ヘパリン組成物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8609632B2 (enExample) |
| EP (3) | EP2447285A3 (enExample) |
| JP (1) | JP2009538386A (enExample) |
| CN (1) | CN101495517B (enExample) |
| AU (1) | AU2007267561B2 (enExample) |
| CA (1) | CA2652205A1 (enExample) |
| WO (1) | WO2007140231A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078960A2 (en) | 2002-03-11 | 2003-09-25 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
| EP2447285A3 (en) | 2006-05-25 | 2013-01-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
| US7968082B1 (en) | 2007-01-26 | 2011-06-28 | Momenta Pharmaceuticals, Inc. | Evaluating mixtures of low molecular weight heparins by NMR |
| US7790466B1 (en) | 2007-01-26 | 2010-09-07 | Momenta Pharmaceuticals, Inc. | Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping |
| US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
| ES2567079T3 (es) | 2007-11-02 | 2016-04-19 | Momenta Pharmaceuticals, Inc. | Composiciones de polisacáridos que no son anticoagulantes |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009105522A1 (en) * | 2008-02-20 | 2009-08-27 | Momenta Pharmaceuticals, Inc. | Methods of making low molecular weight heparin compositions |
| US20100036310A1 (en) * | 2008-08-05 | 2010-02-11 | Hillman Robert S | Integrated patient management and control system for medication delivery |
| CN101711771B (zh) * | 2008-10-07 | 2015-12-09 | 上海喜恩医药科技发展有限公司 | 一种肝素衍生的多糖混合物及其制法和药物组合物 |
| EP2256139A1 (en) * | 2009-05-05 | 2010-12-01 | Sanofi-Aventis | Novel sulfated heptasaccharide and its use as antithrombotic agent |
| EP2256137A1 (en) * | 2009-05-05 | 2010-12-01 | Sanofi-Aventis | Novel sulfated octasaccharide and its use as antithrombotic agent |
| EP2256136A1 (en) * | 2009-05-05 | 2010-12-01 | Sanofi-Aventis | Novel acylated decasaccharides and their use as antithrombotic agents |
| EP2256138A1 (en) * | 2009-05-05 | 2010-12-01 | Sanofi-Aventis | Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent |
| US8834807B2 (en) * | 2009-08-12 | 2014-09-16 | Caliper Life Sciences, Inc. | Device and method for improving sample injection and stacking |
| FR2949114B1 (fr) * | 2009-08-14 | 2011-08-26 | Sanofi Aventis | OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| WO2011031301A2 (en) * | 2009-08-28 | 2011-03-17 | Mount Sinai School Of Medicine Of New York University | Intrapericardial delivery of periostin |
| WO2011038047A1 (en) * | 2009-09-23 | 2011-03-31 | Momenta Pharmaceuticals, Inc. | Methods of treatment with a low molecular weight heparin composition |
| JP5860811B2 (ja) | 2009-12-03 | 2016-02-16 | オプコ ヘルス インコーポレイテッド | 高硫酸化二糖製剤 |
| US8435795B2 (en) * | 2010-01-19 | 2013-05-07 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| CN102985443B (zh) * | 2010-04-16 | 2017-05-10 | 动量制药公司 | 组织靶向 |
| WO2011159770A2 (en) | 2010-06-17 | 2011-12-22 | Momenta Pharmaceuticals, Inc. | Methods and compositions for modulating hair growth |
| US11203772B2 (en) | 2010-12-23 | 2021-12-21 | The University Of North Carolina At Chapel Hill | Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins |
| EP2667186B1 (en) * | 2011-01-28 | 2015-10-14 | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | Fine structure determination method of enoxaparin sodium based on capillary electrophoresis |
| US9068957B2 (en) | 2011-02-21 | 2015-06-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| WO2013095215A1 (en) * | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| SMT201800143T1 (it) * | 2011-12-19 | 2018-05-02 | Dilafor Ab | Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico |
| CN103059165B (zh) * | 2012-12-26 | 2015-04-29 | 安徽丰原药业股份有限公司 | 一种多糖酰化物及其制备方法 |
| CN103204958B (zh) * | 2013-04-24 | 2015-04-01 | 深圳赛保尔生物药业有限公司 | 一种低乙醇残留的那曲肝素钙生产工艺 |
| CA2910837A1 (en) | 2013-05-28 | 2014-12-04 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
| EP3011043B1 (en) * | 2013-06-17 | 2022-05-11 | The University of North Carolina At Chapel Hill | Reversible heparin molecules |
| CN103788232A (zh) * | 2013-12-23 | 2014-05-14 | 深圳市海普瑞药业股份有限公司 | 一种硫酸乙酰肝素十糖及其制备方法和应用 |
| CN104193849B (zh) * | 2014-08-13 | 2016-08-17 | 南京健友生化制药股份有限公司 | 一种依诺肝素钠的生产方法 |
| US10688249B2 (en) * | 2015-06-11 | 2020-06-23 | Virchow Biotech Pvt. Ltd. | Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same |
| CN105504097B (zh) * | 2015-12-30 | 2018-07-03 | 深圳市海普瑞药业集团股份有限公司 | 一种硫酸化肝素寡糖及其制备方法和应用 |
| US20190002596A1 (en) * | 2015-12-30 | 2019-01-03 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Sulfated heparin oligosaccharide and preparation method and application thereof |
| JP6844890B2 (ja) * | 2016-01-07 | 2021-03-17 | 藤森工業株式会社 | 採血管、試薬及びそれらを利用した血液性状分析方法 |
| CN105461831A (zh) * | 2016-01-08 | 2016-04-06 | 东营天东制药有限公司 | 一种快速分离快速移动肝素与硫酸皮肤素的方法 |
| RU2641058C1 (ru) * | 2016-11-17 | 2018-01-15 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Способ профилактики венозной тромбоэмболии у больных раком шейки матки |
| CN108117614B (zh) * | 2016-11-29 | 2020-09-04 | 北京碧澄生物科技有限公司 | 低分子量肝素 |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| CN110446511B (zh) | 2017-03-10 | 2024-04-02 | 北卡罗来纳大学查珀尔希尔分校 | 短效的基于肝素的抗凝血剂化合物和方法 |
| US11993627B2 (en) | 2017-07-03 | 2024-05-28 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides |
| EP3691653B1 (en) | 2017-11-03 | 2025-03-12 | The University Of North Carolina At Chapel Hill | Sulfated oligosaccharides having anti-inflammatory activity |
| EP3810152A4 (en) | 2018-06-20 | 2022-04-27 | The University of North Carolina at Chapel Hill | CELL PROTECTION METHODS AND COMPOSITIONS |
| WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
| CA3144968A1 (en) | 2019-07-09 | 2021-01-14 | Optimvia Llc | Methods for synthesizing anticoagulant polysaccharides |
| US20230241095A1 (en) * | 2020-06-12 | 2023-08-03 | Ihp Therapeutics Inc. | Partially desulfated heparin for treating coronaviral infections |
| BR112023022331A2 (pt) * | 2021-05-12 | 2023-12-26 | Nexeos Diagnostics Inc | Métodos de fabricação de um composto de heparina de alto peso molecular |
| KR20250063537A (ko) * | 2023-11-01 | 2025-05-08 | 건국대학교 글로컬산학협력단 | 저분자량 헤파린 및 지질이 결합되어 자가 조립된 나노 입자, 이의 제조방법 및 이의 용도 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK196986D0 (da) * | 1986-04-30 | 1986-04-30 | Novo Industri As | Fremstilling af polysaccharider |
| FR2663639B1 (fr) | 1990-06-26 | 1994-03-18 | Rhone Poulenc Sante | Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation. |
| US5707973A (en) * | 1991-04-23 | 1998-01-13 | Rhone-Poulenc Rorer S.A. | Sulfated polysaccharids for treatment or prevention of thromboses |
| FR2687158B1 (fr) * | 1992-02-07 | 1995-06-30 | Rhone Poulenc Rorer Sa | Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation. |
| US5849721A (en) * | 1992-02-07 | 1998-12-15 | Rhone-Poulenc Rorer S.A. | Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof |
| US5681733A (en) | 1994-06-10 | 1997-10-28 | Ibex Technologies | Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum |
| FR2723847A1 (fr) * | 1994-08-29 | 1996-03-01 | Debiopharm Sa | Compositions antithrombotiques et non hemorragiques a base d'heparine, procede pour leur preparation et applications therapeutiques. |
| US5744457A (en) * | 1995-03-31 | 1998-04-28 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US5763427A (en) * | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US20010046974A1 (en) * | 1997-06-06 | 2001-11-29 | Hamilton Civic Hospitals Res Dev., Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| AU7753898A (en) * | 1997-06-06 | 1998-12-21 | Hamilton Civic Hospitals Research Development, Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| US5896789A (en) | 1997-10-09 | 1999-04-27 | Chicago Pneumatic Tool Company | Ratchet wrench head |
| JP4226101B2 (ja) | 1998-05-12 | 2009-02-18 | 株式会社アルバック | 静電チャックプレート表面からの基板離脱方法 |
| US20020009782A1 (en) * | 1999-06-03 | 2002-01-24 | Daphna Miron | Heparin and heparan sulfate derived oligosaccharides and a method for their manufacture |
| JP2003504428A (ja) * | 1999-06-30 | 2003-02-04 | ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド | クロット関連凝固因子を阻害するヘパリン組成物 |
| DE10084241D2 (de) | 2000-01-10 | 2003-02-20 | Welzel Dieter | Heparin mit mittlerer Molmasse |
| US6869789B2 (en) * | 2000-03-08 | 2005-03-22 | Massachusetts Institute Of Technology | Heparinase III and uses thereof |
| US6608042B2 (en) * | 2000-03-28 | 2003-08-19 | Aventis Pharma, S.A. | Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof |
| FR2811992B1 (fr) * | 2000-07-21 | 2003-07-04 | Aventis Pharma Sa | Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant |
| US6969705B2 (en) * | 2000-07-21 | 2005-11-29 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| US7083937B2 (en) | 2000-09-12 | 2006-08-01 | Massachusetts Institute Of Technology | Methods and products related to the analysis of polysaccarides |
| EP1328260A2 (en) | 2000-10-18 | 2003-07-23 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
| WO2002086655A2 (en) * | 2001-04-03 | 2002-10-31 | Rx-Connect, Inc. | Permission based marketing for use with medical prescriptions |
| CA2458852A1 (en) * | 2001-08-28 | 2003-03-06 | Leo Pharma A/S | Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate |
| US7084118B2 (en) * | 2002-02-22 | 2006-08-01 | Genentech, Inc. | Combination treatment with t-PA variant and low molecular weight heparin |
| WO2003078960A2 (en) * | 2002-03-11 | 2003-09-25 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
| FR2845686B1 (fr) * | 2002-10-10 | 2013-08-30 | Aventis Pharma Sa | Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2857971B1 (fr) * | 2003-07-24 | 2005-08-26 | Aventis Pharma Sa | Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN1268650C (zh) * | 2003-12-24 | 2006-08-09 | 兆科药业（合肥）有限公司 | 一种低亚硝酸盐含量的低分子肝素钙的制备方法 |
| RU2295538C2 (ru) | 2005-03-01 | 2007-03-20 | Гематологический научный центр РАМН | Способ получения гепаринов с низкой молекулярной массой |
| WO2007127749A2 (en) * | 2006-04-24 | 2007-11-08 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
| EP2447285A3 (en) | 2006-05-25 | 2013-01-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
-
2007
- 2007-05-24 EP EP11172772A patent/EP2447285A3/en not_active Withdrawn
- 2007-05-24 EP EP11172771A patent/EP2404939A3/en not_active Withdrawn
- 2007-05-24 US US11/805,829 patent/US8609632B2/en active Active
- 2007-05-24 JP JP2009512295A patent/JP2009538386A/ja active Pending
- 2007-05-24 EP EP07797722A patent/EP2019843A2/en not_active Withdrawn
- 2007-05-24 AU AU2007267561A patent/AU2007267561B2/en not_active Ceased
- 2007-05-24 WO PCT/US2007/069626 patent/WO2007140231A2/en not_active Ceased
- 2007-05-24 CA CA002652205A patent/CA2652205A1/en not_active Abandoned
- 2007-05-24 CN CN2007800280960A patent/CN101495517B/zh not_active Expired - Fee Related
-
2010
- 2010-05-26 US US12/788,264 patent/US20100305022A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538386A5 (enExample) | ||
| US8609632B2 (en) | Low molecular weight heparin composition and uses thereof | |
| DK2794666T3 (en) | Use of chemically modified heparin derivatives in sickle cell disease | |
| EP1070503B1 (en) | Compositions comprising low molecular weight Heparin | |
| JPH0629282B2 (ja) | 解重合及び超硫酸化ヘパリン、その製造方法並びに製薬組成物 | |
| EP2205642A2 (en) | Non-anticoagulant polysaccharide compositions | |
| RU2010122324A (ru) | Полисахаридные композиции, не обладающие антикоагулянтными свойствами | |
| EP2558124A1 (en) | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization | |
| Fu et al. | Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration | |
| Fareed et al. | Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile | |
| BR112014014454B1 (pt) | glicosaminoglicanos não anti-coagulativos compreendendo unidade de dissacarìdo repetida e seus usos médicos | |
| TW200846014A (en) | Low molecular weight heparins comprising at least one covalent bond with biotin or a biotin derivative, preparation process therefor and use thereof | |
| WO2009105522A1 (en) | Methods of making low molecular weight heparin compositions | |
| US20120322760A1 (en) | Methods of treatment with a low molecular weight heparin composition | |
| JP4051099B2 (ja) | 低分子化ヘパリン、その製造法及び医薬組成物 | |
| JP4897991B2 (ja) | 超低分子量ヘパリン組成物 | |
| EP1731131A1 (en) | Hgf production accelerator containing heparin-like oligosaccharide | |
| JPH10218902A5 (enExample) | ||
| US20070155694A1 (en) | Low molecular weight polysaccharides having antithrombotic activity | |
| Fareed et al. | Low molecular weight heparins: a developmental perspective | |
| RU2008151420A (ru) | Композиции гепарина низкой молекулярной массы и их применение | |
| US7618652B2 (en) | Glycosaminoglycan anticoagulants derived from fish | |
| Messmore et al. | Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review | |
| Mousa | Heparin and low molecular weight heparin in thrombosis, cancer, and inflammatory diseases | |
| Bisio et al. | Carbohydrate‐Based Antithrombotics |